- Home
- FTHM vs LITS Comparison
FTHM vs LITS Comparison
Compare FTHM & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | LITS |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 25.7M |
| IPO Year | 2020 | 2003 |
Fundamental Metrics
Financial Performance| Metric | FTHM | LITS |
|---|---|---|
| Price | $0.38 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 884.6K |
| Earning Date | 11-10-2026 | 09-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | 13.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $9.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $0.69 |
| 52 Week High | $1.92 | $2.97 |
Technical Indicators
Market Signals| Indicator | FTHM | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 60.72 |
| Support Level | $0.40 | $0.88 |
| Resistance Level | $0.92 | $1.61 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 2.38 | 61.47 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.